Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker INFQ
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Jun 11, 2026 | SCHEDULE 13G | INFQ Infleqtion, Inc. | S&G Foundation | 11.57M | 5.3% | SCHEDULE 13G ↗ |
| Jun 9, 2026 | SCHEDULE 13G/A (amended) | INFQ Infleqtion, Inc. | W. Grant Dollens | 4.69M | 2.2% | SCHEDULE 13G/A ↗ |
| Jun 9, 2026 | SCHEDULE 13G/A (amended) | INFQ Infleqtion, Inc. | Global Frontier Quantum Opportunity Fund, LP | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Jun 9, 2026 | SCHEDULE 13G/A (amended) | INFQ Infleqtion, Inc. | Global Frontier Investments LLC | 2.36M | 1.1% | SCHEDULE 13G/A ↗ |
| May 26, 2026 | SCHEDULE 13D/A (amended) | INFQ Infleqtion, Inc. | Maverick Silicon, L.P. | 0 | 0.0% | SCHEDULE 13D/A ↗ |
| May 26, 2026 | SCHEDULE 13D/A (amended) | INFQ Infleqtion, Inc. | David B. Singer | 8.07M | 3.6% | SCHEDULE 13D/A ↗ |
| May 26, 2026 | SCHEDULE 13D/A (amended) | INFQ Infleqtion, Inc. | Lee S. Ainslie III | 8.07M | 3.6% | SCHEDULE 13D/A ↗ |
| May 26, 2026 | SCHEDULE 13D/A (amended) | INFQ Infleqtion, Inc. | Maverick Capital, Ltd. | 8.07M | 3.6% | SCHEDULE 13D/A ↗ |
| May 26, 2026 | SCHEDULE 13D/A (amended) | INFQ Infleqtion, Inc. | Maverick Fund II, Ltd. | 0 | 0.0% | SCHEDULE 13D/A ↗ |
| May 26, 2026 | SCHEDULE 13D/A (amended) | INFQ Infleqtion, Inc. | Maverick Long Enhanced Fund, Ltd. | 0 | 0.0% | SCHEDULE 13D/A ↗ |
| May 26, 2026 | SCHEDULE 13D/A (amended) | INFQ Infleqtion, Inc. | Maverick Long Fund, Ltd. | 0 | 0.0% | SCHEDULE 13D/A ↗ |
| May 26, 2026 | SCHEDULE 13D/A (amended) | INFQ Infleqtion, Inc. | Maverick Designated Investments Fund, L.P. | 0 | 0.0% | SCHEDULE 13D/A ↗ |
| May 26, 2026 | SCHEDULE 13D/A (amended) | INFQ Infleqtion, Inc. | Maverick Fund USA, Ltd. | 0 | 0.0% | SCHEDULE 13D/A ↗ |
| May 26, 2026 | SCHEDULE 13D/A (amended) | INFQ Infleqtion, Inc. | Maverick Silicon Fund, L.P. | 0 | 0.0% | SCHEDULE 13D/A ↗ |
| May 26, 2026 | SCHEDULE 13D/A (amended) | INFQ Infleqtion, Inc. | Maverick Capital Ventures, LLC | 8.07M | 3.6% | SCHEDULE 13D/A ↗ |
| May 26, 2026 | SCHEDULE 13D/A (amended) | INFQ Infleqtion, Inc. | Maverick Advisors Fund, L.P. | 3.12M | 1.4% | SCHEDULE 13D/A ↗ |
| May 26, 2026 | SCHEDULE 13D/A (amended) | INFQ Infleqtion, Inc. | Maverick Ventures Investment Fund, L.P. | 4.95M | 2.3% | SCHEDULE 13D/A ↗ |
| May 26, 2026 | SCHEDULE 13D/A (amended) | INFQ Infleqtion, Inc. | Maverick Capital Management, LLC | 8.07M | 3.6% | SCHEDULE 13D/A ↗ |
| May 26, 2026 | SCHEDULE 13D/A (amended) | INFQ Infleqtion, Inc. | MCV Management Company, LLC | 8.07M | 3.6% | SCHEDULE 13D/A ↗ |
| Apr 28, 2026 | SCHEDULE 13G/A (amended) | INFQ Infleqtion, Inc. | LCP Quantum Management III, LLC | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Apr 28, 2026 | SCHEDULE 13G/A (amended) | INFQ Infleqtion, Inc. | LCP Quantum Management, LLC | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Apr 28, 2026 | SCHEDULE 13G/A (amended) | INFQ Infleqtion, Inc. | LCP Quantum Partners VI, LLC | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Apr 28, 2026 | SCHEDULE 13G/A (amended) | INFQ Infleqtion, Inc. | LCP Quantum Partners V, LLC | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Apr 28, 2026 | SCHEDULE 13G/A (amended) | INFQ Infleqtion, Inc. | LCP Quantum Partners IV, LLC | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Apr 28, 2026 | SCHEDULE 13G/A (amended) | INFQ Infleqtion, Inc. | LCP Quantum Partners III, LLC | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Apr 28, 2026 | SCHEDULE 13G/A (amended) | INFQ Infleqtion, Inc. | LCP Quantum Partners II, LLC | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Apr 28, 2026 | SCHEDULE 13G/A (amended) | INFQ Infleqtion, Inc. | LCP Quantum Partners, LLC | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Apr 28, 2026 | SCHEDULE 13G/A (amended) | INFQ Infleqtion, Inc. | Tyler Brous | 1.41M | 0.7% | SCHEDULE 13G/A ↗ |
| Mar 10, 2026 | SCHEDULE 13G | INFQ Infleqtion, Inc. | John James | 12.45M | 5.8% | SCHEDULE 13G ↗ |
| Mar 10, 2026 | SCHEDULE 13G | INFQ Infleqtion, Inc. | BOKA Group Holdings GP LLC | 12.45M | 5.8% | SCHEDULE 13G ↗ |
| Mar 10, 2026 | SCHEDULE 13G | INFQ Infleqtion, Inc. | BOKA Group Holdings I LP | 12.45M | 5.8% | SCHEDULE 13G ↗ |
| Feb 27, 2026 | SCHEDULE 13G | INFQ Infleqtion, Inc. | LCP Quantum Management III, LLC | 13.07M | 6.0% | SCHEDULE 13G ↗ |
| Feb 27, 2026 | SCHEDULE 13G | INFQ Infleqtion, Inc. | LCP Quantum Management, LLC | 17.46M | 8.0% | SCHEDULE 13G ↗ |
| Feb 27, 2026 | SCHEDULE 13G | INFQ Infleqtion, Inc. | LCP Quantum Partners VI, LLC | 640,000 | 0.3% | SCHEDULE 13G ↗ |
| Feb 27, 2026 | SCHEDULE 13G | INFQ Infleqtion, Inc. | LCP Quantum Partners V, LLC | 2.82M | 1.3% | SCHEDULE 13G ↗ |
| Feb 27, 2026 | SCHEDULE 13G | INFQ Infleqtion, Inc. | LCP Quantum Partners IV, LLC | 1.81M | 0.8% | SCHEDULE 13G ↗ |
| Feb 27, 2026 | SCHEDULE 13G | INFQ Infleqtion, Inc. | LCP Quantum Partners III, LLC | 7.80M | 3.6% | SCHEDULE 13G ↗ |
| Feb 27, 2026 | SCHEDULE 13G | INFQ Infleqtion, Inc. | LCP Quantum Partners II, LLC | 3.10M | 1.4% | SCHEDULE 13G ↗ |
| Feb 27, 2026 | SCHEDULE 13G | INFQ Infleqtion, Inc. | LCP Quantum Partners, LLC | 14.36M | 6.6% | SCHEDULE 13G ↗ |
| Feb 27, 2026 | SCHEDULE 13G | INFQ Infleqtion, Inc. | Tyler Brous | 30.56M | 14.1% | SCHEDULE 13G ↗ |
| Feb 23, 2026 | SCHEDULE 13G | INFQ Infleqtion, Inc. | W. Grant Dollens | 25.71M | 11.9% | SCHEDULE 13G ↗ |
| Feb 23, 2026 | SCHEDULE 13G | INFQ Infleqtion, Inc. | Global Frontier Quantum Opportunity Fund, LP | 20.84M | 9.6% | SCHEDULE 13G ↗ |
| Feb 23, 2026 | SCHEDULE 13G | INFQ Infleqtion, Inc. | Global Frontier Investments LLC | 25.62M | 11.8% | SCHEDULE 13G ↗ |
| Feb 18, 2026 | SCHEDULE 13D | INFQ Infleqtion, Inc. | Maverick Silicon, L.P. | 2.88M | 1.3% | SCHEDULE 13D ↗ |
| Feb 18, 2026 | SCHEDULE 13D | INFQ Infleqtion, Inc. | David B. Singer | 16.07M | 7.4% | SCHEDULE 13D ↗ |
| Feb 18, 2026 | SCHEDULE 13D | INFQ Infleqtion, Inc. | Lee S. Ainslie III | 19.98M | 9.2% | SCHEDULE 13D ↗ |
| Feb 18, 2026 | SCHEDULE 13D | INFQ Infleqtion, Inc. | Maverick Capital, Ltd. | 17.10M | 7.9% | SCHEDULE 13D ↗ |
| Feb 18, 2026 | SCHEDULE 13D | INFQ Infleqtion, Inc. | Maverick Fund II, Ltd. | 135,800 | 0.1% | SCHEDULE 13D ↗ |
| Feb 18, 2026 | SCHEDULE 13D | INFQ Infleqtion, Inc. | Maverick Long Enhanced Fund, Ltd. | 143,900 | 0.1% | SCHEDULE 13D ↗ |
| Feb 18, 2026 | SCHEDULE 13D | INFQ Infleqtion, Inc. | Maverick Long Fund, Ltd. | 75,700 | 0.0% | SCHEDULE 13D ↗ |
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 7:24 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances